Clinical Trial

A Phase I Clinical Study of VSA012 in Healthy Volunteers

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The complement system is an important component of the innate immune system. Abnormal activation, inadequate regulation and control of the complement system, as well as impaired and dysfunctional effector functions, underlie complement mediated diseases. VSA012 targeting complement system has the potential to treat a variety of diseases associated with abnormal activation of the complement system (e.g. PNH) .The purpose of VSA012-1001 is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VSA012 Injection in adult healthy volunteers (HVs). HVs will receive a single dose of VSA012 or placebo.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-04.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-04-28
Trial Details
NCT Number NCT06766929
Lead Sponsor Bisirna Therapeutics (Suzhou) Co., Ltd.
Conditions Healthy Volunteers
Enrollment 40 participants
Start Date 2025-01-20
Primary Completion 2026-08 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-04